Imugene Limited's (ASX:IMU) (OTCMKTS:IUGNF) Leslie Chong caught up with Proactive's Andrew Scott following the news California-based investment bank Roth Capital Partners has initiated coverage with a Buy rating and a 12-month price target of 13 cents. She says it's a great accomplishment for them to be told they're a buy and that's only on three of their compounds.
viewImugene Ltd
Imugene's Leslie Chong says Roth Capital Partners' report is 'great accomplishment'
Quick facts: Imugene Ltd
Price: 0.11 AUD
ASX:IMU
Market: ASX
Market Cap: $521.5 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
Imugene progresses towards human studies for PD1-Vaxx treatment by the...
Most read
Mining
AVZ Minerals testing confirms primary lithium sulphate is suitable for...
6 days, 20 hours ago
Mining
Piedmont Lithium enhances senior management team as it drives integrated US...
5 days, 18 hours ago
Mining
European Lithium skyrockets as institutional and high net worth investors...
16 hours, 37 minutes ago
Retail & consumer
S&P/ASX 200 jumps 1.19% to near its highest level in seven sessions
19 hours, 2 minutes ago
